O
CGON icon

OrbiMed’s CG Oncology CGON Stock Holding History

OrbiMed’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,000
Closed -$3.9M – 112
2025
Q2 		$3.9M Buy
+150,000
New +$3.61M 0.1% 81

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed's CGON Position: Q2 2026 in Review

OrbiMed increased its CG Oncology (CGON) stake by 2.6% in Q2 2026, buying an estimated $1.6M and bringing the position to 972,800 shares worth $69.1M. The position accounts for 1.28% of the portfolio, ranked #21.

OrbiMed first reported a position in CGON in Q3 2024 and has held it in 8 quarters since. The position peaked at $69.6M in Q3 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • OrbiMed held 972,800 shares of CG Oncology worth $69.1M as of Q2 2026.
  • OrbiMed bought 24,533 CG Oncology shares in Q2 2026, an estimated $1.6M.
  • CG Oncology made up 1.28% of OrbiMed's portfolio in Q2 2026, its #21 holding.
  • OrbiMed first reported a position in CG Oncology in Q3 2024 and has held it in 8 quarters since.
  • OrbiMed's CG Oncology position peaked at $69.6M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.